Malecare Responds to the New York Times About the High Costs of Advanced Prostate Cancer Treatments
Darryl, the Malecare Executive Director, posted an organizational response to yesterday's New York Times Article on the newly approved advanced prostate cancer drugs and their economic impact. I thought that I would share his insightful post with everyone. "We can easily price commodities and drugs to whatever the market will bare, but how do we [...]